Article

Metabolic vulnerabilities in Down syndrome B-cell acute lymphoblastic leukemia can be targeted using Venetoclax

2024-10-01

Abstract excerpt

Children with Down syndrome (DS) and B-cell acute lymphoblastic leukemia (B-ALL) are at increased risk for treatment-related mortality and relapse, highlighting the need for new therapies. Leukemia cell lines (CLs) have been fundamental to understanding therapeutic responses to pharmacological agents. We generated three DS B-ALL CLs characterized with diverse genomic alterations, including IGH::CRLF2 rearrangemen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e61addad-9914-5be0-98cf-96cfa54d36c5
DOI: 10.1101/2024.09.30.615872

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Metabolic vulnerabilities in Down syndrome B-cell acute lymphoblastic leukemia can be targeted using VenetoclaxDOI 10.1101/2024.09.30.615872Read

Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemiaSemantic proximity Read

Down syndrome and leukemia: An insight into the disease biology and current treatment options.Semantic proximity Read

Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell linesSemantic proximity Read

Multi-omics molecular phenotyping of childhood acute lymphoblastic leukemia cell lines reveals novel drug vulnerabilitiesSemantic proximity Read

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesSemantic proximity Read

Drug response profiling guides precision therapy in relapsed and refractory childhood acute lymphoblastic leukemiaSemantic proximity Read

Unveiling the omics tapestry of B-acute lymphoblastic leukemia: bridging genomics, metabolomics, and immunomicsSemantic proximity Read

Down syndrome preleukemia and leukemia.Semantic proximity Read

Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia.Semantic proximity Read

Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell LeukemiaSemantic proximity Read

Defining the fetal origin of MLL-AF4 infant leukemia highlights specific fatty acid requirementsSemantic proximity Read

Down syndrome and leukemia: from basic mechanisms to clinical advancesSemantic proximity Read